Edwards Lifesciences Corp
EWEdwards Lifesciences Corp (EW) specializes in medical technologies primarily focused on heart valve disease and critical care monitoring. The company is known for its innovations in minimally invasive heart valve repair and replacement, including transcatheter aortic valve replacement (TAVR) devices, as well as advanced hemodynamic monitoring systems. Founded in 1958, Edwards Lifesciences is a leading player in the cardiovascular medical device industry, dedicated to improving patient outcomes through innovative solutions.
Company News
TRiCares has enrolled the first patient in its TRICURE US IDE pivotal study for the Topaz tricuspid valve replacement system, marking the first randomized controlled trial comparing an investigational TTVR device against Edwards' commercially available EVOQUE system. The global study will involve up to 75 sites across the US, Canada, and Europe, ...
The Centers for Medicare & Medicaid Services (CMS) proposed removing coverage with evidence development (CED) requirements for Transcatheter Aortic Valve Replacement (TAVR) in symptomatic severe aortic stenosis patients and expanding coverage to asymptomatic cases under CED. Edwards Lifesciences, which holds the only FDA-approved TAVR device for ...
Edwards Lifesciences reported strong Q1 2026 earnings, beating consensus on both earnings (78 cents vs. 73 cents) and sales ($1.65B vs. $1.59B). The company saw 16.7% year-over-year sales growth driven by robust demand for heart valve therapies, particularly in TAVR and transcatheter mitral/tricuspid procedures. The company raised its 2026 EPS gu...
ORBIMED Advisors LLC reduced its stake in Terns Pharmaceuticals by 5.4 million shares ($125 million) in Q4 2025, though the stock surged 858% over the past year. The clinical-stage biotech company, focused on NASH and metabolic disease treatments, now represents 1.78% of the fund's portfolio. Investors should monitor upcoming clinical trial data ...
The global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. marke...
